AbbVie (ABBV) Stock Forecast & Price Target

→ Has Trump Finally Gone Too Far? (From Insiders Exposed) (Ad)

$171.35

+1.67 (+0.98%)

(As of 06/18/2024 ET)

AbbVie - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 14 Analyst Ratings

Consensus Price Target

$179.64
4.84% Upside

High Forecast	$200.00
Average Forecast	$179.64
Low Forecast	$150.00

Type	Current Forecast 6/20/23 to 6/19/24	1 Month Ago 5/21/23 to 5/20/24	3 Months Ago 3/22/23 to 3/21/24	1 Year Ago 6/20/22 to 6/20/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	11 Buy rating(s)	9 Buy rating(s)	6 Buy rating(s)
Hold	2 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)	8 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$179.64	$176.14	$175.36	$163.40
Forecasted Upside	4.84% Upside	12.86% Upside	13.59% Upside	8.82% Upside

Get AbbVie Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

Ad Priority Gold

Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

Get your free information kit NOW, before it's too late.

ABBV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABBV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AbbVie Stock vs. The Competition

Type	AbbVie	Medical Companies	S&P 500
Consensus Rating Score	2.86	2.70	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	4.84% Upside	1,068.18% Upside	11.31% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/18/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$185.00 ➝ $190.00	+11.96%
6/5/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$185.00	+14.08%
5/17/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$200.00	+21.69%
4/29/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$195.00 ➝ $187.00	+16.84%
4/29/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$195.00 ➝ $180.00	+12.25%
3/22/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$188.00 ➝ $190.00	+6.41%
Get the Latest News and Ratings for ABBV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.
2/6/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$180.00 ➝ $195.00	+13.58%
2/5/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$181.00 ➝ $189.00	+12.05%
1/29/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Lugo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
12/11/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$173.00	+15.89%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$150.00	+5.60%
10/30/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$193.00 ➝ $196.00	+35.90%
10/20/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$157.00 ➝ $150.00	+3.08%
7/28/2023	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$163.00 ➝ $170.00	+12.63%
7/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$170.00 ➝ $160.00	+18.02%
4/28/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$200.00 ➝ $195.00	+30.99%
4/5/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/22/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Peer Perform
2/10/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$157.00 ➝ $154.00	+1.83%
2/10/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform	$135.00 ➝ $153.00	+2.89%
2/10/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Market Perform	$135.00 ➝ $153.00	+2.89%
11/8/2022	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$155.00 ➝ $140.00	-7.32%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:00 AM ET.

ABBV Forecast - Frequently Asked Questions

What is AbbVie's stock forecast and purchase recommendation?: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for AbbVie is $179.64, with a high forecast of $200.00 and a low forecast of $150.00. The consensus rating for AbbVie stock is Moderate Buy based on the current 2 hold ratings and 12 buy ratings for ABBV. Learn more on ABBV's analyst rating history.
Do Wall Street analysts like AbbVie more than its competitors?: Analysts like AbbVie more than other "medical" companies. The consensus rating score for AbbVie is 2.86 while the average consensus rating score for "medical" companies is 2.70. Learn more on how ABBV compares to other companies.
Is AbbVie being upgraded by Wall Street analysts?: Over the previous 90 days, AbbVie's stock had 1 upgrade by analysts.

Does AbbVie's stock price have much upside?: According to analysts, AbbVie's stock has a predicted upside of 13.58% based on their 12-month stock forecasts.
What analysts cover AbbVie?: AbbVie has been rated by research analysts at Barclays, BMO Capital Markets, Cantor Fitzgerald, Guggenheim, HSBC, and Piper Sandler in the past 90 days.